摘要
目的研究柳氮磺胺吡啶联合益生菌治疗炎症性结肠炎的临床意义.方法选择2014-05/2015-05在浙江省丽水市人民医院治疗炎症性肠炎患者78例,随机数字分成研究组和对照组,各39例.对照组采用柳氮磺胺吡啶治疗,研究组采用柳氮磺胺吡啶联合益生菌共同治疗,观察2组临床疗效、内镜复查效果、炎症因子水平及疾病活动指数(disease activity index,DAI)变化.结果治疗后,研究组临床疗效、内镜复查疗效均优于对照组(94.87%vs 64.10%,89.74%vs58.97%),差异有统计学意义(P<0.05);研究组DAI评分低于对照组(3.13±1.08 vs 6.08±1.12),差异有统计学意义(P<0.05);研究组炎症因子水平值低于对照组(肿瘤坏死因子-?:75.68±20.31 vs 96.24±20.64,白介素-6:95.56±23.74 vs 120.37±25.25),差异有统计学意义(P<0.05).结果对炎症性肠炎患者采用益生菌辅助柳氮磺胺吡啶治疗的疗效更好,能抵制炎症发生,降低DAI,可推广应用.
AIM To evaluate the clinical effects of suffasalarin combined with probiotics in the treatment of inflammatory bowel disease.METHODS From May 2014 to May 2015,78 patients with inflammatory bowel disease treated at Lishui People＇s Hospital were randomly divided into a study group and a control group,with 39 cases in each group.The control group was treated with sulfasalazine alone,and the study group was treated with sulfasalazine combined with probiotics.Clinical improvement,endoscopic improvement,inflammatory factor levels,and disease activity index（DAI） were compared between the two groups.RESULTS After treatment,the rates of clinical improvement and endoscopic improvement were significantly better in the study group than in the control group（94.87%us 64.10%,89.74%us58.97%,P〈0.05）;DAI score was significantly lower in the study group than in the control group（3.13±1.08 us 6.08±1.12,P〈0.05）;the levels of inflammatory factors were significantly lower in the study group than in the control group（tumor necrosis factor-α：75.68±20.31 us 96.24±20.64;IL-6：95.56±23.74 us 120.37±25.25,P〈0.05）.CONCLUSION The use of probiotics in patients with inflammatory bowel disease can resist inflammation and reduce DAI
出处
《世界华人消化杂志》
CAS
2017年第3期293-297,共5页
World Chinese Journal of Digestology
关键词
炎症性肠炎
益生菌
柳氮磺胺吡啶
炎症因子
疗效
Inflammatory bowel disease
Probiotics
Suffasalarin
Inflammatory factors
Curative effect
作者简介
叶洁桐，主治医师，主要从事炎症性肠病、消化性溃疡、酒精性肝病等方面的研究．通讯作者：叶洁桐，主治医师，323000，浙江省丽水市莲都区大众街15号，丽水市人民医院消化内科．yangliliqq123@163.com电话：0578—2780124
